161 related articles for article (PubMed ID: 36582798)
1. Economic evaluation of first-line sugemalimab plus chemotherapy for metastatic non-small cell lung cancer in China.
Wang H; Liao L; Xu Y; Long Y; Wang Y; Zhou Y
Front Oncol; 2022; 12():1081750. PubMed ID: 36582798
[TBL] [Abstract][Full Text] [Related]
2. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of sugemalimab in combination with chemotherapy as first-line treatment in Chinese patients with metastatic NSCLC.
Chen P; Li Y; Jing X; Chen J; Chen S; Yang Q
Lung Cancer; 2022 Dec; 174():157-164. PubMed ID: 36413882
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of sugemalimab vs. chemotherapy as first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Zheng Z; Zhu H; Fang L; Cai H
Front Pharmacol; 2022; 13():996914. PubMed ID: 36172187
[No Abstract] [Full Text] [Related]
5. The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China.
Cheng R; Zhou Z; Liu Q
Adv Ther; 2023 Oct; 40(10):4298-4309. PubMed ID: 37453992
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of sugemalimab vs. placebo, in combination with chemotherapy, for treatment of first-line metastatic NSCLC in China.
Li W; Wan L
Front Public Health; 2022; 10():1015702. PubMed ID: 36408023
[TBL] [Abstract][Full Text] [Related]
7. Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
Chen X; Zhao M; Tian L
Front Pharmacol; 2023; 14():1119906. PubMed ID: 37021058
[No Abstract] [Full Text] [Related]
8. Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non-small cell lung cancer in China.
Liu H; Wang Y; He Q
Health Econ Rev; 2022 Dec; 12(1):66. PubMed ID: 36581793
[TBL] [Abstract][Full Text] [Related]
9. Economic Evaluation of Cisplatin Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine for the Treatment of First-Line Advanced Metastatic Triple-Negative Breast Cancer in China: Using Markov Model and Partitioned Survival Model.
Rui M; Shi F; Shang Y; Meng R; Li H
Adv Ther; 2020 Sep; 37(9):3761-3774. PubMed ID: 32647912
[TBL] [Abstract][Full Text] [Related]
10. Comparing the cost-effectiveness of sintilimab + pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer.
Shi Y; Qian D; Li Y; Chen W; Bo M; Zhang M; Shi J; Jia B; Dai Y; Li G
Transl Cancer Res; 2023 Apr; 12(4):928-938. PubMed ID: 37180653
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of camrelizumab plus chemotherapy vs. chemotherapy in the first-line treatment of non-squamous NSCLC: Evidence from China.
Dai H; Wang W; Fan X; Chen Y
Front Med (Lausanne); 2023; 10():1122731. PubMed ID: 36865055
[TBL] [Abstract][Full Text] [Related]
12. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.
Li W; Wan L
PLoS One; 2023; 18(6):e0286595. PubMed ID: 37262075
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China.
Liu Q; Luo X; Peng L; Yi L; Wan X; Zeng X; Tan C
BMJ Open; 2020 Nov; 10(11):e040691. PubMed ID: 33243806
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness Analysis of Atezolizumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer With Different PD-L1 Expression Status.
Liu G; Kang S; Wang X; Shang F
Front Oncol; 2021; 11():669195. PubMed ID: 33987103
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum
Cai Y; Hui W; Zhu M; Zhang M; Gao Z; Wu H
Front Oncol; 2021; 11():768035. PubMed ID: 34900717
[TBL] [Abstract][Full Text] [Related]
17. Cost-Utility Analysis of Camrelizumab Plus Chemotherapy Versus Chemotherapy Alone as a First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer in China.
Chen T; Xie R; Zhao Q; Cai H; Yang L
Front Oncol; 2022; 12():746526. PubMed ID: 35936702
[TBL] [Abstract][Full Text] [Related]
18. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
19. Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China.
Zhou C; Wei J; Xu K; Lin Y; Zhang L; Li X
Risk Manag Healthc Policy; 2023; 16():2447-2458. PubMed ID: 38024498
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of Atezolizumab Combination Therapy for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer in the United States.
Criss SD; Mooradian MJ; Watson TR; Gainor JF; Reynolds KL; Kong CY
JAMA Netw Open; 2019 Sep; 2(9):e1911952. PubMed ID: 31553470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]